Earnings Summary

Agios Pharmaceuticals, Inc.’s revenue jumped 46% since last year same period to $8.19Mn in the Q1 2024. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated 15.29% jump in its revenue since last 3-months.

Agios Pharmaceuticals, Inc.’s net profit fell -14.18% since last year same period to $-81.55Mn in the Q1 2024. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated 15% jump in its net profits since last 3-months.

Agios Pharmaceuticals, Inc.’s net profit margin jumped 21.79% since last year same period to -995.84% in the Q1 2024. On a quarterly growth basis, Agios Pharmaceuticals, Inc. has generated 26.27% jump in its net profit margins since last 3-months.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.6 - a 3.03% jump from last quarter’s estimates.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -1.6.

Agios Pharmaceuticals, Inc.’s earning per share (EPS) jumped 1.36% since last year same period to -1.45 in the Q1 2024. This indicates that the Agios Pharmaceuticals, Inc. has generated 1.36% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Agios Pharmaceuticals, Inc.’s return on assets (ROA) stands at -0.25.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Agios Pharmaceuticals, Inc.’s return on equity (ROE) stands at -0.4.